Biomarkers

A new WHO resolution highlights the growing global commitment to equitable access to precision medicine and biomarker testing.

Denelle shares her experience with early-onset colorectal cancer.

Cheri shares her CRC experience from asymptomatic screening to treatment of Stage IV colorectal cancer.

Nicole Sheahan blogs from the FT3 board meeting in Croatia.

Global Colon Cancer Association, FUTEJE, and From Testing to Targeted Treatment Launch New Collaboration During Colorectal Cancer Awareness Month

What does HER2 positive mean for people with CRC?

Understanding an important biomarker in colorectal cancer.

Survey findings highlight need for improved education and access to precision medicine in the Japanese American community.

Key takeaways on tumor sidedness.

Why does waiting for biomarker testing results matter in colorectal cancer?

Genetic testing changed, and saved, Dan's life.

Troy's life was saved by biomarker testing.

GCCA launches Knowing Is Worth the Wait campaign.

The third blog in a series focused on Know Your Biomarker Tumor Sidedness.

The second blog in a series focused on Know Your Biomarker Tumor Sidedness.

The first blog in a series focused on Know Your Biomarker Tumor Sidedness.

Highlights of GCCA's work with the Japanese American community.

GCCA President, Nicole Sheahan, shares highlights from four transformative meetings.

Learn about GCCA's participation in the BLOODPAC meeting.

Learn about DPD deficiency and its relevance in cancer treatment.

GCCA President and From Testing to Targeted Treatments Board Member, Nicole Sheahan, blogs from a meeting in Morocco.

Learn more about GCCA's partnership with the BLOODPAC Consortium.